167 related articles for article (PubMed ID: 1705643)
1. Biological therapy for metastatic renal cell cancer.
Lancet; 1991 Mar; 337(8740):522-3. PubMed ID: 1705643
[No Abstract] [Full Text] [Related]
2. Systemic therapy of metastatic renal cell carcinoma.
Vugrin D
Semin Nephrol; 1987 Jun; 7(2):152-62. PubMed ID: 2442806
[No Abstract] [Full Text] [Related]
3. Renal cell carcinoma and interleukin-2: a review.
Wagstaff J; Baars JW; Wolbink GJ; Hoekman K; Eerenberg-Belmer AJ; Hack CE
Eur J Cancer; 1995; 31A(3):401-8. PubMed ID: 7540404
[No Abstract] [Full Text] [Related]
4. Metastatic renal cell carcinoma: systemic treatment.
Abi-Aad AS; deKernion JB
Acta Urol Belg; 1996 May; 64(2):3-8. PubMed ID: 8701805
[No Abstract] [Full Text] [Related]
5. Interferons and interleukins in metastatic renal cell carcinoma.
Choudhury M; Efros M; Mittelman A
Urology; 1993 Jan; 41(1 Suppl):67-72. PubMed ID: 7678365
[TBL] [Abstract][Full Text] [Related]
6. The role of cytokines in the therapy of renal cell carcinoma.
Ebert T; Schmitz-Dräger BJ; Ackermann R
Recent Results Cancer Res; 1993; 126():113-8. PubMed ID: 7681213
[No Abstract] [Full Text] [Related]
7. [The value of interferons, interleukin-2 and tumor necrosis factor in the therapy of renal cell cancer].
Wirth M
Urologe A; 1991 Mar; 30(2):77-80. PubMed ID: 1711729
[TBL] [Abstract][Full Text] [Related]
8. [The immunotherapy of advanced renal cell carcinoma].
Bergmann L; Weidmann E; Mitrou PS
Dtsch Med Wochenschr; 1991 Mar; 116(10):384-90. PubMed ID: 1705879
[No Abstract] [Full Text] [Related]
9. Biologic response modifiers in the therapy of metastatic renal cell carcinoma.
Quesada JR
Semin Oncol; 1988 Aug; 15(4):396-407. PubMed ID: 2457256
[No Abstract] [Full Text] [Related]
10. Immunotherapy for metastatic renal cell carcinoma.
Wirth MP
Urol Clin North Am; 1993 May; 20(2):283-95. PubMed ID: 7684167
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers.
Mani S; Todd MB; Katz K; Poo WJ
J Urol; 1995 Jul; 154(1):35-40. PubMed ID: 7539867
[TBL] [Abstract][Full Text] [Related]
12. [Immunotherapy of metastatic renal cell cancer].
Manseck A; Wirth M
Urologe A; 1993 Sep; 32(5):360-73. PubMed ID: 7692655
[TBL] [Abstract][Full Text] [Related]
13. The use of interferon in renal cell carcinoma.
Muss HB
Eur J Cancer; 1991; 27 Suppl 4():S84-7. PubMed ID: 1724728
[TBL] [Abstract][Full Text] [Related]
14. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
[TBL] [Abstract][Full Text] [Related]
15. The current use of interferons, interleukin-2 and tumor necrosis factor in renal cell cancer.
Wirth M
Urol Int; 1991; 47(4):219-30. PubMed ID: 1723554
[TBL] [Abstract][Full Text] [Related]
16. Renal-cell carcinoma.
Atkins MB; Dutcher JP
N Engl J Med; 1997 Mar; 336(11):809; author reply 810-1. PubMed ID: 9064517
[No Abstract] [Full Text] [Related]
17. Cellular therapy: scientific rationale and clinical results in the treatment of metastatic renal-cell carcinoma.
Pierce WC; Belldegrun A; Figlin RA
Semin Oncol; 1995 Feb; 22(1):74-80. PubMed ID: 7855622
[No Abstract] [Full Text] [Related]
18. [Has interleukin 2 modified the outcome of metastatic kidney cancer?].
Négrier S; Philip T
Ann Urol (Paris); 1993; 27(2):87-9. PubMed ID: 8503657
[TBL] [Abstract][Full Text] [Related]
19. [The role of immunotherapy in metastatic cancer of the kidney].
Thiounn N
J Urol (Paris); 1994; 100(5):231-7. PubMed ID: 7730669
[TBL] [Abstract][Full Text] [Related]
20. Combination biologic therapy with interleukin-2 and interferon-alfa in the outpatient treatment of metastatic renal cell carcinoma.
Figlin RA; Pierce WC; Belldegrun A
Semin Oncol; 1993 Dec; 20(6 Suppl 9):11-5. PubMed ID: 8284686
[No Abstract] [Full Text] [Related]
[Next] [New Search]
